Humans are around 30 trillion cells In our adult bodies. Amazingly, each of those cells got here from a handful of about 100 Stem cells In the early days of development. The ability of those embryonic stem cells to rework into any sort of cell makes them pluripotent — something researchers are using in science and medicine today.
Use of human embryonic stem cells in research Started in 1998when multiple human embryos were donated from couples undergoing in vitro fertilization. From these embryos, scientists generated a virtually unlimited supply of pluripotent cells. Nearly 30 years later, these embryonic stem cell lines are still utilized in many research labs today.
Another milestone in stem cell research got here in 2007, when two labs—led by Shinya Yamanaka i Kyoto University By and in Japan James Thompson i University of Wisconsin-Madison In the United States – individually published papers on how they reprogrammed mature cells (resembling skin cells) right into a stem cell-like pluripotent state.
These are often called induced pluripotent stem cells. Their essential advantage is that they contain an individual’s own DNA, allowing for more personalized disease modeling and treatment.
How can stem cells be used to treat diabetes?
In our research lab, we use embryonic stem cells to provide insulin-producing beta cells—the sort of cell that’s destroyed by the immune system in people. Type 1 diabetes. Loss of those insulin-producing beta cells leaves patients depending on insulin injections to regulate blood sugar levels and forestall serious complications resembling blood vessel and nerve damage.
Insulin therapy doesn’t provide relief Emotional burden Living with Type 1 Diabetes. It also doesn’t completely change the way in which the body’s own beta cells work, so many individuals with type 1 diabetes still experience it. Long-term health problems.
To overcome this, researchers are growing the lab. Stem cell-derived beta cells Trying to revive the body’s ability to provide insulin. Recent clinical trials Transplantation of those cells in individuals with type 1 diabetes has shown promising results:
-
Vertex Pharmaceuticals Twelve patients with type 1 diabetes were transplanted with beta cells derived from embryonic stem cells, and 10 (83 percent) were in a position to stop insulin injections inside six months.
-
Oh Research team reprogrammed the fat cells of a sort 1 diabetic patient from China into induced pluripotent stem cells, transformed the induced pluripotent stem cells into beta cells, after which transplanted them under the patient’s abdominal muscles. Notably, the recipient became insulin independent 75 days after surgery and remained so for at the very least 12 months.
These early trials show that stem cell-derived beta cells can survive, mature and performance after transplantation into patients. But Challenges remainThis includes ensuring that the cell sort of interest is fully developed, producing the cells safely and efficiently on a big scale and inhibiting the immune response.
(OpenAI ChatGPT/DALL·E).
How can stem cells avoid the immune response?
The lab-grown cells have different genetics than the patient, so the patient’s immune system attacks the transplanted cells as “non-self.”
Researchers and clinicians are hoping to beat this problem through the use of induced pluripotent stem cells that carry the patient’s own DNA. However, even “self-derived” cells can. Behave unexpectedly After months of reprogramming and development within the lab, the immune response due to this fact stays a threat.
And in diseases like type 1 diabetes, the cells can still be. destroyed by a single autoimmune response Which caused the disease in the primary place.
While Immune-suppressing drugs Currently used to forestall rejection, they carry serious risks that outweigh the advantages for many patients.
Researchers at the moment are searching for ways to forestall cell rejection without the necessity for immune-suppressing drugs, resembling using Protective capsule that protect the transplanted cells or introduce genetic changes that help the cells “hide” from the immune system.
The promise of immune-evading genetically modified cells was recently demonstrated in a. 2025 study When researchers transplanted gene-modified cells right into a patient with type 1 diabetes without using immune-suppressing drugs. Remarkably, the patient had no immune response to the transplanted cells, which survived, secreted insulin and improved blood sugar control at 12 weeks.
The breakthrough highlights the potential of immune cell therapies to beat one in all the most important hurdles in regenerative medicine.
The road ahead
Stem cells offer a unprecedented toolkit for scientific research and medicine. Researchers are improving at turning these pluripotent cells into specialized tissues and the primary successful clinical trials are already here. However, these treatments are still experimental and never yet approved by Health Canada or the Food and Drug Administration within the United States.
Patients needs to be wary of unapproved stem cell therapies and all the time seek the advice of their healthcare skilled before engaging. Approved clinical trials. The progress made up to now raises real hope that future stem cell therapies could improve the lives of individuals with chronic diseases.